Lurasidone's US approval a milestone event for DSP
This article was originally published in Scrip
In a key development for the company, Dainippon Sumitomo Pharma's (DSP) atypical antipsychotic lurasidone has been approved in the US, as Latuda, for the first-line treatment of adult schizophrenia.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.